^
    2d
    Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov)
    P1, N=23, Terminated, Xencor, Inc. | N=128 --> 23 | Active, not recruiting --> Terminated; Business Decision
    Enrollment change • Trial termination
    8d
    A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (clinicaltrials.gov)
    P1/2, N=33, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed | N=150 --> 33 | Trial completion date: Mar 2027 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date
    15d
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    21d
    A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (clinicaltrials.gov)
    P3, N=124, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    24d
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Suspended --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    1m
    ALLELE: A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy (clinicaltrials.gov)
    P3, N=115, Recruiting, Pierre Fabre Medicament | N=66 --> 115
    Enrollment change
    |
    Rituxan (rituximab) • Tab-cel (tabelecleucel)
    1m
    MARCH: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=244, Active, not recruiting, Vir Biotechnology, Inc. | Trial completion date: Jun 2027 --> Mar 2026 | Trial primary completion date: Jun 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    2ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Suspended, Dwight Owen | Recruiting --> Suspended
    Trial suspension
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    2ms
    ALLELE: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (clinicaltrials.gov)
    P3, N=66, Recruiting, Pierre Fabre Medicament | Trial primary completion date: Aug 2025 --> May 2030
    Trial primary completion date
    |
    Rituxan (rituximab) • Tab-cel (tabelecleucel)
    2ms
    MELODY-1: A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Microbiotica Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    2ms
    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (clinicaltrials.gov)
    P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial primary completion date • Platinum resistant
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • olvimulogene nanivacirepvec (GL-ONC1)
    3ms
    Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
    P1, N=8, Terminated, Eureka Therapeutics Inc. | Phase classification: P1/2 --> P1
    Phase classification
    |
    AFP (Alpha-fetoprotein)
    |
    ET140203